June 4, 2020 / 5:14 AM / a month ago

BRIEF-Galapagos And Gilead Sciences: Filgotinib Shows Efficacy And Safety Profile At 52 Weeks In FINCH 1 And 3 Studies

June 4 (Reuters) - Galapagos NV:

* FILGOTINIB DEMONSTRATES DURABLE EFFICACY AND CONSISTENT SAFETY PROFILE AT 52 WEEKS IN FINCH 1 AND 3 STUDIES IN RHEUMATOID ARTHRITIS

* DATA PRESENTED AT EUROPEAN LEAGUE AGAINST RHEUMATISM, EULAR, EUROPEAN E-CONGRESS OF RHEUMATOLOGY 2020

* INTEGRATED SAFETY ANALYSIS FROM PHASE 3 FINCH AND PHASE 2 DARWIN PROGRAMS INFORMS LONG-TERM SAFETY PROFILE OF FILGOTINIB IN RA Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below